Clinical Trial Update: Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens [NA]

View source ↗

Summary

ARTIDIS AG is evaluating nanomechanical signature profiling on pancreatic cancer specimens in a clinical trial. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Snippet

Sponsor: ARTIDIS AG | Conditions: Pancreatic Cancer, Pancreatic Neoplasms | NA | Status: RECRUITING